ArticleCurrent treatment options in cardiovascular medicine2015
Engineered Tissue Patch for Cardiac Cell Therapy.
Article in Current treatment options in cardiovascular medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Bioactive Scaffolds in Stem Cell-Based Therapies for Myocardial Infarction: a Systematic Review and Meta-Analysis of Preclinical Trials.Stem cell reviews and reports · 2022Pooled it
- Progress and challenges in transplantation of human pluripotent stem cell derived cardiomyocytes for cardiac therapy.npj biomedical innovations · 2026Review
- Cardiac Tissue Engineering for Translational Cardiology: From In Vitro Models to Regenerative Therapies.Bioengineering (Basel, Switzerland) · 2025Review
- Model construction and clinical therapeutic potential of engineered cardiac organoids for cardiovascular diseases.Biomaterials translational · 2024Review
- Detergent-Based Decellularization for Anisotropic Cardiac-Specific Extracellular Matrix Scaffold Generation.Biomimetics (Basel, Switzerland) · 2023Article
- Latest Advances in 3D Bioprinting of Cardiac Tissues.Advanced materials technologies · 2022Article
- Pre-Conditioning Methods and Novel Approaches with Mesenchymal Stem Cells Therapy in Cardiovascular Disease.Cells · 2022Review
- Review
- 3D bioprinting of stem cell-laden cardiac patch: A promising alternative for myocardial repair.APL bioengineering · 2021Review
- Polymeric Biomaterials for the Treatment of Cardiac Post-Infarction Injuries.Pharmaceutics · 2021Review
- Cardiac Organoids to Model and Heal Heart Failure and Cardiomyopathies.Biomedicines · 2021Review
- Electroactive Polymeric Composites to Mimic the Electromechanical Properties of Myocardium in Cardiac Tissue Repair.Gels (Basel, Switzerland) · 2021Review
- Engineering Human Cardiac Muscle Patch Constructs for Prevention of Post-infarction LV Remodeling.Frontiers in cardiovascular medicine · 2021Review
- Adhesive Tissue Engineered Scaffolds: Mechanisms and Applications.Frontiers in bioengineering and biotechnology · 2021Review
- Scaffold-Mediated Developmental Effects on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Are Preserved After External Support Removal.Frontiers in cell and developmental biology · 2021Article
- Review Insights In Cardiac Tissue Engineering: Cells, Scaffolds, and Pharmacological Agents.Iranian journal of pharmaceutical research : IJPR · 2021Review
- Engineered biomaterials for heart disease.Current opinion in biotechnology · 2020Review
- Bioresorbable Polymeric Scaffold in Cardiovascular Applications.International journal of molecular sciences · 2020Review
- A Visible Light-Cross-Linkable, Fibrin-Gelatin-Based Bioprinted Construct with Human Cardiomyocytes and Fibroblasts.ACS biomaterials science & engineering · 2019Article
- In Vivo Assessment of Decellularized Porcine Myocardial Slice as an Acellular Cardiac Patch.ACS applied materials & interfaces · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
opinion statementCell therapy can be administered via injections delivered directly into the myocardium or as engineered cardiac tissue patches, which are the subject of this review. Engineered cardiac patches can be created from sheets of interconnected cells or by suspending the cells in a scaffold of material that is designed to mimic the native extracellular matrix. The sheet-based approach produces patches with well-aligned and electronically coupled cardiomyocytes, but cell-containing scaffolds are more readily vascularized by the host's circulatory system and, consequently, are currently more suitable for applications that require a thicker patch. Cell patches can also be modified for the co-delivery of peptides that may promote cell survival and activate endogenous repair mechanisms; nevertheless, techniques for controlling inflammation, limiting apoptosis, and improving vascular growth need continue to be developed to make it a therapeutic modality for patients with myocardial infarction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.